CTOR vs. PGEN, TNGX, CMRX, BTMD, SNDL, TRVI, YMAB, VYGR, ITOS, and IMMP
Should you be buying Citius Oncology stock or one of its competitors? The main competitors of Citius Oncology include Precigen (PGEN), Tango Therapeutics (TNGX), Chimerix (CMRX), biote (BTMD), SNDL (SNDL), Trevi Therapeutics (TRVI), Y-mAbs Therapeutics (YMAB), Voyager Therapeutics (VYGR), iTeos Therapeutics (ITOS), and Immutep (IMMP). These companies are all part of the "pharmaceutical products" industry.
Citius Oncology vs.
Citius Oncology (NASDAQ:CTOR) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, community ranking, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.
In the previous week, Precigen had 3 more articles in the media than Citius Oncology. MarketBeat recorded 6 mentions for Precigen and 3 mentions for Citius Oncology. Precigen's average media sentiment score of 0.77 beat Citius Oncology's score of 0.75 indicating that Precigen is being referred to more favorably in the news media.
Citius Oncology has a net margin of 0.00% compared to Precigen's net margin of -3,521.68%. Citius Oncology's return on equity of -90.25% beat Precigen's return on equity.
Citius Oncology currently has a consensus price target of $3.00, indicating a potential upside of 183.02%. Precigen has a consensus price target of $6.33, indicating a potential upside of 483.72%. Given Precigen's higher possible upside, analysts clearly believe Precigen is more favorable than Citius Oncology.
70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 22.9% of Citius Oncology shares are held by insiders. Comparatively, 44.9% of Precigen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Citius Oncology has a beta of -0.64, indicating that its share price is 164% less volatile than the S&P 500. Comparatively, Precigen has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.
Citius Oncology has higher earnings, but lower revenue than Precigen.
Precigen received 434 more outperform votes than Citius Oncology when rated by MarketBeat users. However, 100.00% of users gave Citius Oncology an outperform vote while only 67.34% of users gave Precigen an outperform vote.
Summary
Precigen beats Citius Oncology on 8 of the 15 factors compared between the two stocks.
Get Citius Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Citius Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:CTOR) was last updated on 1/15/2025 by MarketBeat.com Staff
